We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

CAROLINA LIQUID CHEMISTRIES

Carolina Liquid Chemistries offers a complete line of clinical chemistry analyzers and reagents for use on common pla... read more Featured Products: More products

Download Mobile App




Carolina Liquid Chemistries and Diazyme Enter Into Partnership

By LabMedica International staff writers
Posted on 24 Jan 2023

Carolina Liquid Chemistries, Corp. More...

(CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.

In comparison to using time-consuming and labor-intensive immunoassay platforms, it is more economical to run tests on clinical chemistry analyzers. The DZ-Lite c270 is an advanced benchtop clinical chemistry analyzer with a menu of FDA-cleared, moderately complex, and innovative assays made for clinical laboratories of all sizes. The compact clinical chemistry analyzer supports 1, 2, 3, and 4-part reagent assays and has a throughput of up to 270 tests per hour. The analyzer can be used in all types of clinical laboratory settings such as reference laboratories, hospitals, and physician offices with clinical labs.

Related Links:
Carolina Liquid Chemistries, Corp. 
Diazyme Laboratories, Inc. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.